You searched for "Lucentis"

277 results found

Discussing treatment modalities for bilateral wet AMD

A 65-year-old lady with bilateral wet AMD and vision of 6/24 comes with an internet search about current therapies. How do you explain the various treatment modalities available? There are two NICE approved treatments for wet age-related macular degeneration (AMD)....

Licence to save: a UK survey of anti-VEGF use for the eye

This comment article highlights the controversy that exists in the choice for anti-VEGF drugs used for treatment of macular oedema and wet age-related macular degeneration (AMD). Two existing licensed drugs for macular oedema are ranibizumab (Lucentis) and aflibercept (Eylea). A...

Effect of minor trauma in eyes with previously undiagnosed angioid streaks

Angioid streaks (AS) may be associated with pseudoxanthoma elasticum (PXE), Paget’s disease, haemoglobulinopathies, Ehlers-Danlos Syndrome or abetalipoproteinaemia. Histopathology showed retinal pigment epithelium (RPE) and choriocapillaris loss, elastic fibre degeneration, calcium deposition, active choroidal neovascular membrane (CNVM) and vascular endothelial growth...

Andy Biart joins Carleton Optical as Surgical Business Manager, South

Carleton are pleased to welcome Andy Biart to their surgical team.

Outcomes at 100 weeks from the LEAVO study of intravitreal anti-VEGF therapies for macular oedema secondary to central retinal vein occlusion

Royal College of Ophthalmologists Annual Congress 2019, Glasgow - First presented and discussed on Monday 20 May 2019, with a further presentation of results during Retina Subspecialty Day on Thursday 23 May 2019. Among patients with macular oedema secondary to...

A look into the IOL space

Advances in the design and performance of intraocular lenses (IOLs) continue to be driven by demand for better outcomes, presbyopia correction and spectacle independence, alongside a better understanding of the dynamics of the crystalline lens, newer theories of accommodation and...

Ocular manifestation of Marfan Syndrome

This repeated cross-sectional study collected data in 2003-2004 and 2014-2015 to investigate changes in ocular features in Marfan syndrome (MFS) fulfilling the Ghent-2 criteria. Ghent-2 is a set of criteria by which MFS are identified and includes aortic root aneurysm...

Evaluation of ectopia lentis et pupillae (ELP)

The ADAMTSL4 gene encodes proteins for cellular adhesion, angiogenesis, nervous system development and anterior / posterior segment structures. This case report describes a four-year-old female with diagnosis at referral of ELP. A three-generation pedigree was obtained and was negative for...

Childhood headaches

The goal of this study was to compare headache resolution in children receiving or not receiving refractive correction. The authors conducted a retrospective review of 158 patients: 78 male and 80 female aged three to twelve years (mean eight). Twenty-seven...

More sensitive visual acuity test for age-related macular degeneration

Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world. Primarily associated with ageing, genetic factors and lifestyle choices such as smoking also play a contributory role. Patients with early AMD, characterised by the development of...

Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice

The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...

Corporate M&A pace gathers momentum

Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...